Causes, symptoms, and management of non-metastatic castration-resistant prostate cancer

Causes, symptoms, and management of non-metastatic castration-resistant prostate cancer

Prostate cancer develops when abnormal cells grow in the prostate gland. At times, the condition advances to a stage where it neither spreads nor does it respond to regular cancer treatments. This stage is called non-metastatic castration-resistant prostate cancer (nmCRPC). Here, the cancerous cells might grow, but they do not affect organs other than the prostate. Fortunately, today, there are a few ways to manage this advanced cancer stage in consultation with a healthcare expert.

Causes
Non-metastatic castration-resistant prostate cancer (nmCRPC) is an advanced form of prostate cancer, the exact cause of which is yet to be determined. That said, prostate cancer itself develops when cells in the organ undergo DNA changes. These alterations compel the cells to grow and divide more rapidly than normal cells. Eventually, the accumulation of abnormal cells can spread to nearby tissues if not promptly treated.

Symptoms
Those with nmCRPC usually do not notice any symptoms and will be unable to tell if the cancer is growing. Only a healthcare professional would be able to confirm the condition after noticing an increase in the prostate-specific antigen (PSA) level. These changes are tracked with the help of blood tests, physical examinations, and scans, including bone, PET, and CT scans. One might be able to get a diagnosis early if they are able to notice any unusual changes and get examined by a doctor immediately.  

Management options
One of the primary goals of nmCRPC treatment is to delay any potential spread and manage existing symptoms. There are a few options to consider here.

1. Active surveillance
The method involves tracking the growth of the cancer to delay or completely avoid aggressive therapy.

2. Androgen deprivation therapy (ADT)
Also known as hormone therapy, this option helps slow the growth of cancer. ADT can be of various types and may involve a combination of surgery and prescription treatment. 

3. Second-line anti-androgen treatment
This treatment might be recommended in combination with ADT to stop or slow the spread of cancer.